Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Tourmaline Bio's share price for the quarter that ended in Mar. 2024 was $22.9. Tourmaline Bio's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 25.65 Mil. Therefore, Tourmaline Bio's market cap for the quarter that ended in Mar. 2024 was $587.30 Mil.
Tourmaline Bio's quarterly market cap
increased
from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($532.44 Mil) and
increased
from Dec. 2023 ($532.44 Mil) to Mar. 2024 ($587.30 Mil).
Tourmaline Bio's annual market cap
stayed the same
from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then
increased
from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($532.44 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Tourmaline Bio's Enterprise Value for Today is $52.26 Mil.
Tourmaline Bio Market Cap Historical Data
The historical data trend for Tourmaline Bio's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Tourmaline Bio's Market Cap
For the Biotechnology subindustry, Tourmaline Bio's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tourmaline Bio's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tourmaline Bio's Market Cap distribution charts can be found below:
* The bar in red indicates where Tourmaline Bio's Market Cap falls into.
Tourmaline Bio Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Tourmaline Bio's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tourmaline Bio (NAS:TRML) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Tourmaline Bio Market Cap Related Terms
Thank you for viewing the detailed overview of Tourmaline Bio's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Tourmaline Bio (Tourmaline Bio) Business Description
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TRML has been successfully added to your 